Common name:







Uses of sodium Pamidronate

Pamidronate is an aminobis phosphonate with general properties similar to other bisphosphonates and inhibits bone resorption but appears to have less effect on bone mineralization than comparable doses of etidornate. Sodium pamidorant is used as an adjunct therapy in severe hypercalcemia, especially when associated with malignancy. It is also used to treat osteolytic lesions and bone pain in multiple myeloma or bone metastases from breast cancer. It may be used in bone disorders with extensive bone resorption, as seen in Paget’s bone disease.

Mechanism of action of sodium Pamidronate

It is a bisphosphonate derivative that inhibits bone resorption by acting on osteoclasts.

Pharmacokinetics of sodium pamidronate

After administration and readmission of sodium disodium pamidronate, between 20 and 55% of the prescribed dose is excreted unchanged in the urine within 72 hours, while most of the remaining amount is trapped in the bone and slowly disappears. In patients with severe renal impairment, renal clearance is slower and infusion rates may need to be reduced. Sodium pamidronate has poor digestive absorption (about 1 to 3%).

Side effects of sodium pamidronate

Central nervous system: fatigue, headache, insomnia, anxiety, pain
Endocrinology and metabolism: Decreased blood phosphate, Decreased blood potassium, Decreased blood calcium, Decreased blood magnesium
Gastrointestinal: nausea, vomiting, anorexia, abdominal pain, indigestion
Genitourinary: Urinary tract infection
Hematology and oncology: anemia, metastasis, granulocytopenia
Topical: Infusion site reaction (including redness, callus, pain, swelling)
Nervous, muscular and skeletal: muscle pain, weakness, bone pain, joint pain
Renal: Increased serum creatinine
Respiratory: Shortness of breath, upper respiratory tract infection, cough, sinusitis, dehydration
Miscellaneous: Fever
Cardiovascular: Atrial fibrillation, hypertension, syncope, tachycardia, atrial flutter, heart failure, edema
Central nervous system: drowsiness, psychosis
Endocrinology and metabolism: Hypothyroidism
Gastrointestinal: constipation, gastrointestinal bleeding, diarrhea, inflammation of the mouth
Genitourinary: Urea in the blood
Hematology and oncology: leukopenia, neutropenia, thrombocytopenia
Infectious: Candidiasis
Nervous, muscular and skeletal: arthropathy, low back pain
Renal: Kidney insufficiency
Respiratory: Ral (abnormal lung sound), rhinitis
Other complications (percentage unknown):
Endocrinology and Metabolism: Hyperolmia (increased intravascular volume)

Drug Interactions Sodium Pamidronate

Exacerbation of hypocalcemia
Exacerbation of hypophosphatemia
Exacerbation of renal toxicity

Reducing the effects of drugs with Pamidronate:

No significant interference has been identified.

Reducing the effects of Pamidronate by drugs:

Proton pump inhibitors

Enhance the effects of drugs with pamidronate:


Increased effects of pamidronate by drugs:

Aminoglycosides, systemic angiogenesis inhibitors, nonsteroidal anti-inflammatory drugs, thalidomide

Food interference:

has not been stated.

Precautions Sodium pamidronate

Pamidronate should be used with caution in patients with heart disease, in patients undergoing thyroid surgery, and in patients with severe upper gastrointestinal disorders.
This medicine should not be used as a single intravenous injection.
Serum calcium and phosphate electrolytes should be measured regularly during treatment
The rate of infusion in patients with severe renal impairment needs to be adjusted

Sodium pamidronate drug recommendations

The patient should be advised to adjust their diet, limit their activity, and use anti-nausea medications in case of nausea and vomiting.
Fever is a common complication of pamidronate that usually resolves on its own. Fatigue and drowsiness are also common side effects of this drug.
If you feel burning, numbness, stomach pain, irritation or pain at the injection site, fatigue, edema, nausea, anorexia, diarrhea, constipation, vomiting, insomnia, inflammation of the mouth, difficulty breathing, muscle pain and difficulty passing Tell your doctor about urination
In cases of Paget’s disease or osteolytic lesions, multiple myeloma, the patient should receive sufficient fluids.

Was this helpful?

0 / 0

Leave a Reply 0

Your email address will not be published. Required fields are marked *